{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:40:31Z","timestamp":1754163631878,"version":"3.41.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,31]]},"DOI":"10.7759\/cureus.89108","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:25:28Z","timestamp":1753950328000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ustekinumab in Treatment of Ulcerative Colitis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Yashasvi","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehal K","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samyuktha","family":"Harikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanathanan","family":"Neelakantan Ramaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalvin","family":"Chand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manvitha","family":"Bendagiri Matam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin DT","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019, 114:384-413. 10.14309\/ajg.0000000000000152","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre C","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023, 402:571-84. 10.1016\/S0140-6736(23)00966-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.02.050","article-title":"Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial","volume":"20","author":"Danese S","year":"2022","unstructured":"Danese S, Sands BE, Abreu MT, et al.. Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial. Clin Gastroenterol Hepatol. 2022, 20:2858-2867.e5. 10.1016\/j.cgh.2022.02.050","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein JD","year":"2019","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019, 94:1357-73. 10.1016\/j.mayocp.2019.01.018","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro F","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, et al.. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017, 11:649-70. 10.1093\/ecco-jcc\/jjx008","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein JD","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020, 158:1450-61. 10.1053\/j.gastro.2020.01.006","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord M","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al.. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017, 11:769-84. 10.1093\/ecco-jcc\/jjx009","journal-title":"J Crohns Colitis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot A","year":"2020","unstructured":"Amiot A, Filippi J, Abitbol V, et al.. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020, 51:1039-46. 10.1111\/apt.15717","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18999\/nagjms.85.3.402","article-title":"Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis","volume":"85","author":"Uchida G","year":"2023","unstructured":"Uchida G, Nakamura M, Yamamura T, Tsuzuki T, Kawashima H. Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a systematic review and meta-analysis. Nagoya J Med Sci. 2023, 85:402-27. 10.18999\/nagjms.85.3.402","journal-title":"Nagoya J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae023","article-title":"Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study","volume":"6","author":"Parra RS","year":"2024","unstructured":"Parra RS, Chebli JM, de Azevedo MF, et al.. Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study. Crohns Colitis 360. 2024, 6:otae023. 10.1093\/crocol\/otae023","journal-title":"Crohns Colitis 360"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2021.","article-title":"Ustekinumab (Stelara)","author":"Canadian Agency for Drugs and Technologies in Health","year":"2017","unstructured":"Canadian Agency for Drugs and Technologies in Health. Ustekinumab (Stelara). Canadian Agency for Drugs and Technologies in Health, Ottawa; 2017. 10.1016\/j.radcr.2021."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al.. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019, 381:1201-14. 10.1056\/NEJMoa1900750","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI long-term maintenance study","volume":"119","author":"Afif W","year":"2024","unstructured":"Afif W, Arasaradnam RP, Abreu MT, et al.. Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI long-term maintenance study. Am J Gastroenterol. 2024, 119:910-21. 10.14309\/ajg.0000000000002621","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100070","article-title":"Unmet needs in inflammatory bowel disease","volume":"2","author":"Rev\u00e9s J","year":"2021","unstructured":"Rev\u00e9s J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021, 2:100070. 10.1016\/j.crphar.2021.100070","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002854","article-title":"Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE)","volume":"36","author":"Sabhan H","year":"2024","unstructured":"Sabhan H, Bello F, Muhsen S, et al.. Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE). Eur J Gastroenterol Hepatol. 2024, 36:1419-25. 10.1097\/MEG.0000000000002854","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002939","article-title":"Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study","volume":"37","author":"Molander P","year":"2025","unstructured":"Molander P, Af Bj\u00f6rkesten CG, Henricson H, et al.. Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study. Eur J Gastroenterol Hepatol. 2025, 37:446-53. 10.1097\/MEG.0000000000002939","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab070","article-title":"Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro M","year":"2021","unstructured":"Chaparro M, Garre A, Iborra M, et al.. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021, 15:1846-51. 10.1093\/ecco-jcc\/jjab070","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: unifi long-term extension","volume":"16","author":"Abreu MT","year":"2022","unstructured":"Abreu MT, Rowbotham DS, Danese S, et al.. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: unifi long-term extension. J Crohns Colitis. 2022, 16:1222-34. 10.1093\/ecco-jcc\/jjac030","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.037","article-title":"Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis","volume":"159","author":"Li K","year":"2020","unstructured":"Li K, Marano C, Zhang H, et al.. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology. 2020, 159:2052-64. 10.1053\/j.gastro.2020.08.037","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-4599","article-title":"Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis","volume":"31","author":"Affendi NA","year":"2022","unstructured":"Affendi NA, Ooi CJ, Hilmi IN. Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis. J Gastrointestin Liver Dis. 2022, 31:478-9. 10.15403\/jgld-4599","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich M","year":"2019","unstructured":"Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019, 50:992-1006. 10.1016\/j.immuni.2019.03.017","journal-title":"Immunity"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis P","year":"2022","unstructured":"Pavlidis P, Tsakmaki A, Pantazi E, et al.. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat Commun. 2022, 13:5820. 10.1038\/s41467-022-33331-8","journal-title":"Nat Commun"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.12.011","article-title":"Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis","volume":"18","author":"Pai RK","year":"2020","unstructured":"Pai RK, Hartman DJ, Rivers CR, Regueiro M, Schwartz M, Binion DG, Pai RK. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020, 18:2510-2517.e5. 10.1016\/j.cgh.2019.12.011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab007","article-title":"Full, partial, and modified permutations of the mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients","volume":"3","author":"Naegeli AN","year":"2021","unstructured":"Naegeli AN, Hunter T, Dong Y, et al.. Full, partial, and modified permutations of the mayo score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients. Crohns Colitis 360. 2021, 3:otab007. 10.1093\/crocol\/otab007","journal-title":"Crohns Colitis 360"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392683-efficacy-and-safety-of-ustekinumab-in-treatment-of-ulcerative-colitis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T08:25:29Z","timestamp":1753950329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392683-efficacy-and-safety-of-ustekinumab-in-treatment-of-ulcerative-colitis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.89108","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}